Validation of the prophylactic efficacy of urea-based creams on sorafenib-induced hand-foot skin reaction in patients with advanced hepatocellular carcinoma: A randomised experiment study

Ru-Yu Lien, Heng-Hsin Tung, Shang-Laing Wu, Sophia H Hu, Ling-Chun Lu, Shu-Fen Lu, Ru-Yu Lien, Heng-Hsin Tung, Shang-Laing Wu, Sophia H Hu, Ling-Chun Lu, Shu-Fen Lu

Abstract

Background: Hand-foot skin reaction may influence the effectiveness of patients' treatment, patient quality of life, and the economics of health care. An effective prophylactic dermatological cream for preventing sorafenib-induced hand-foot skin reaction (HFSR) is yet to be identified.

Aim: The aim of this study is validated the prophylactic efficacy of urea-based creams on sorafenib-induced hand-foot skin reaction in patients with advanced hepatocellular carcinoma.

Methods: This was a randomised double-blind experimental study. A total of 129 patients with advanced HCC were randomly assigned to three groups. The comparison group received best supportive care (BSC), group A received BSC plus a moisturising cream, and group B received BSC plus a 10% urea-based cream. Incidence of HFSR and cutaneous wetness were assessed 3 days before starting sorafenib and each week after starting sorafenib for 8 weeks.

Results: No significant difference was observed in the incidence density of sorafenib-induced HFSK (comparison group/A group, p > .05; comparison group/B group, p > .05). Group B reported significantly better cutaneous wetness of hands in the seventh week after starting sorafenib (p < .05) and of feet during the first 6 weeks (p < .05-.001).

Conclusion: This study found a nut size amount of a 10% urea-based cream applied twice a day can maintain patients' cutaneous wetness in the first 6 weeks after starting sorafenib than moisturising-alone cream. But it cannot reduce the occurrence of HFSR. Thus, the result supports nut-size dose of the 10% urea-based cream three times a day may be an appropriate dose to prevent HFSR. Clinical Trail Registration Number: NCT04568330.

Keywords: head-foot skin reaction; hepatocellular carcinoma; side effect of Sorafenib; symptom management.

Conflict of interest statement

The authors declared that they have no conflict of interest to this work.

© 2021 The Authors. Cancer Reports published by Wiley Periodicals LLC.

Figures

FIGURE 1
FIGURE 1
CONSORT diagram of patients included in the study
FIGURE 2
FIGURE 2
Changes in mean cutaneous wetness in hands and feet

References

    1. Albreht T, Borras J, Conroy F. European Guide for Quality National Cancer Control Programs. Ljubljana: European Partnership for Action against Cancer; 2015.
    1. Bray F, Ferlay J, Soerjomataram I. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. Cancer J Clin. 2018;68:394‐424.
    1. European Association for the Study of the Liver . EASL clinical practice guidelines: management of hepatocellular carcinoma. J Hepatol. 2018;69:182‐236.
    1. Vogel A, Cervantes A, Chau I. Hepatocellular carcinoma: ESMO clinical practice guidelines for diagnosis, treatment and follow‐up. Ann Oncol. 2018;S4:iv238‐iv255.
    1. Llovet JM, Ricci S, Mazzaferro V. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med. 2008;359:378‐390.
    1. Cheng AL, Kang YK, Chen Z. Efficacy and safety of sorafenib in patients in the Asia‐Pacific region with advanced hepatocellular carcinoma: a phase III randomized double‐blind, placebo‐controlled trail. Lancet Oncol. 2009;10:25‐34.
    1. National Comprehensive Cancer Network . NCCN clinical practice guidelines in oncology (NCCN Guidelines): hepatobiliary cancers. Accessed August 1, 2019. .
    1. Cubero DIG, Abdalla BMZ, Schoueri J. Cutaneous side effect of molecularly targeted therapies for the treatment of solid tumors. Drug Context. 2018;7:212516.
    1. Lipworth AD, Robet C, Zhu AX. Hand‐foot syndrome (head‐foot skin reaction, palmar‐plantar erythrodysesthesia): focus on Sorafenib and Sunitinib. Oncology. 2009;77:257‐271.
    1. Massey PR, Okman JS, Wilkerson J. Tyrosine kinase inhibitors directed against the vascular endothelial growth factor receptor (VEGFR) have distinct cutaneous toxicity profiles: a meta‐analysis and review of the literature. Support Care Cancer. 2015;23(6):1827‐1838.
    1. Chang WT, Lu SN, Rau KM. Increase cumulative doses and appearance of hand‐foot skin reaction prolonged progression free survival in sorafenib‐treated advanced hepatocellular carcinoma patients. Kaohsiung J Med. 2018;34:391‐399.
    1. Kao PH, Cen JS, Chung WH. Cutaneous adverse events of targeted anticancer therapy: a review of common clinical manifestations and management. J Cancer Res Pract. 2015;2(4):271‐284.
    1. Macdonald JB, Macdonald B, Golitz LE. Cutaneous adverse side effects of targeted therapy – part I: inhibitors of the cellular membrane. J Am Acad Dermatol. 2015;72(2):203‐218.
    1. Manchen E, Robert C, Porta C. Management of tyrosine kinase inhibitor‐induced hand‐foot skin reaction: viewpoints from the medical oncologist, dermatologist, and oncology nurse. J Support Oncol. 2011;9(1):13‐23.
    1. Wood LS, Lemont H, Jatoi A. Practical considerations in the management of hand‐foot skin reaction caused by multikinase inhibitors. Commun Oncol. 2010;7:23‐39.
    1. Celleno L. Topical urea in skincare: a review. Dermatol Ther. 2018;31:e12690.
    1. Ren ZG, Zhu KS, Kng HY. Randomized controlled trial of the prophylactic effect of urea‐based cream on sorafenib‐associated hand‐foot skin reaction in patients with advanced hepatocellular carcinoma. J Clin Oncol. 2015;33:894‐900.
    1. Negri FV. Urea‐based cream to prevent sorafenib‐induced hand‐and‐foot skin reaction: which evidence? J Clin Oncol. 2015;33(28):3219.
    1. Faul F, Erdfelder E, Bunchner A, Lang AG. Statistical power analysis using G*power 3.1: test for correlation and regression analysis. Behav Res Methods. 2009;41(4):1149‐1160.
    1. Dueck AC, Mendoza TR, Mitchell SA. Validity and reliability of the US National Cancer Institute's patient‐reported outcomes version of the common terminology criteria for adverse events (PRO‐CTAE). JAMA Oncol. 2015;1(8):1051‐1059.
    1. Piccoli A, Rossi B, Pillon L, Bucciante G. A new method for monitoring body fluid variation by bioimpedance analysis: the RXc graph. Kidney Int. 1994;46:534‐539.
    1. Shinohara N, Nonmura N, Eto M. A randomized multicenter phase II trial on the efficacy of a hydrocolloid dressing contain ceramide with a low‐friction external surface for hand‐foot skin reaction caused by sorafenib in patients with renal cell carcinoma. Ann Oncol. 2014;25:472‐476.
    1. Barton‐Burke M, Ciccolini K, Mekas M. Dermatologic reactions to targeted therapy: a focus on epidermal growth factor receptor inhibitors and nursing care. Nurs Clin North Am. 2017;52(1):83‐113.

Source: PubMed

스폰서 및 공동 작업자

건강 상태

약물 개입

3
구독하다